<DOC>
	<DOC>NCT01739647</DOC>
	<brief_summary>This is a single dose study in healthy male and female (of non-child bearing potential) volunteers, to assess the safety, effects on the body, and blood and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease</brief_summary>
	<brief_title>A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects</brief_title>
	<detailed_description>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers</detailed_description>
	<criteria>Healthy male and female (of nonchildbearing potential) subjects Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg History or presence of psychiatric disease/condition, GI, renal, hepatic, cardiovascular, psychiatric, or retinal diseases or disorders History of neurological disease, including seizures, recent memory impairment, or clinically significant head injury History of use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other nicotine products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>AZD3293</keyword>
	<keyword>Healthy volunteers</keyword>
	<keyword>Elderly volunteers</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Single Ascending Dose Study</keyword>
</DOC>